ArticleClinical cancer research : an official journal of the American Association for Cancer Research2022

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy.

Daniel M Girardi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.